Cullinan Therapeutics (CGEM) Net Income towards Common Stockholders (2020 - 2026)

Cullinan Therapeutics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$52.4 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 7.47% year-over-year to -$52.4 million; the TTM figure through Mar 2026 stood at -$224.8 million (up 28.16% YoY), while the FY2025 annual figure was -$219.9 million, down 66.39% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$52.4 million, down from -$50.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $174.1 million in Q2 2022, with the low at -$178.5 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$45.0 million (2024), against an average of -$38.4 million.
• Peak annual rise in Net Income towards Common Stockholders reached 1158.85% in 2022, while the deepest fall reached 1008.53% in 2022.
• Cullinan Therapeutics' Net Income towards Common Stockholders stood at -$27.0 million in 2022, then plunged by 98.86% to -$53.8 million in 2023, then tumbled by 231.83% to -$178.5 million in 2024, then surged by 71.62% to -$50.7 million in 2025, then slipped by 3.35% to -$52.4 million in 2026.
• Business Quant data shows CGEM's Net Income towards Common Stockholders at -$52.4 million in Q1 2026, -$50.7 million in Q4 2025, and -$51.7 million in Q3 2025.